World’s first rapid saliva-based pregnancy test developed
Salignostics completes clinical trials of revolutionary SaliStick home test kit for pregnancy, based on its technology for detecting Covid-19.
Salignostics completes clinical trials of revolutionary SaliStick home test kit for pregnancy, based on its technology for detecting Covid-19.
Jewish, Muslim, Christian and Baháʼí leaders agree on religious obligation to save lives and the effectiveness and safety of the vaccine.
A new device assesses bloodflow and oxygen in the feet to detect a problem early, while treatment options are still open.
Coalition for Epidemic Preparedness Innovations grant will help establish proof of concept for vaccines protective against existing and new strains.
New nanotech approach to breast cancer targets the nervous system around the tumor, inhibiting growth and metastasis.
‘Elimination means bringing cases down to sufficiently low numbers, so that no community transmission occurs for extended periods of time.’
‘All the evidence shows that the virus severely damages the blood vessels or the endothelial cells that line the blood vessels.’
Kahun’s intelligent chatbot is designed to aid in the diagnostic process in conjunction with one’s physician.
Neuromagen Pharma secures funding to test a new class of small molecules to treat amyotrophic lateral sclerosis and other neurodegenerative diseases.
Study is first to estimate effectiveness of a third dose of an mRNA Covid-19 vaccine against severe outcomes and within subgroups.
A watershed mark in the corona pandemic: As of November 1, individual tourists may enter Israel, under certain conditions.
Experiments in mice show prolonged normal blood sugar levels after a single autograft procedure using their own engineered muscle cells.
‘I want any teenager with problems to know that life doesn’t end with school,’ says Shilo Ben Zeev. ‘If you push your dream and don’t give up, you can do a lot.’
Study finds certain immune cells sometimes ‘switch sides’ and actually help tumors grow; finding has implications for improving immunotherapy
Israeli study also shows 93% effectiveness in preventing the spread of symptomatic infection within seven to 21 days of the second Pfizer dose.